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We read with interest the study by Kebapcilar et al.1 on
the effect of Helicobacter pylori (HP) eradication on serum
fetuin-A concentrations. Specifically, baseline serum fetuin-
A was lower in HP-positive participants than in HP-
negative matched participants. Furthermore, fetuin-A levels
significantly increased after successful HP eradication
treatment.1 To our knowledge, this is the first report on
the effect of HP eradication on serum fetuin-A.
Recently, Manolakis et al. proposed serum fetuin-A as a
mediator linking HP infection and insulin resistance (IR).2
This is also an interesting concept with therapeutic potential
because it suggests that HP eradication might decrease IR
and IR-related morbidity, including type II diabetes mellitus
(T2DM), nonalcoholic fatty liver disease (NAFLD) and
cardiovascular disease (CVD),3 although the effect on CVD
is highly debatable.4 We have recently performed a
systematic review on the association between HP infection
and IR.5 Existing data indicate a potential association
between HP infection and IR, as assessed by homeostatic
model assessment IR (HOMA-IR). However, although
histology is considered the gold standard diagnostic test
for HP, some studies used other methods to determine HP
status. The serum anti-HP-specific IgG antibody level may
be of diagnostic value, but it does not discriminate between
past and current infections. Furthermore, given that serum
remains positive for anti-HP-specific IgG even after eradica-
tion of HP, it is unclear whether HP infection is the inducer
or the promoter of IR.5
However, in the study by Manolakis et al., baseline fetuin-
A was higher in HP-positive participants than in HP-
negative participants.2 The reason for this discrepancy
between the two studies1,2 is largely unknown. Both studies
recruited non-diabetic patients with dyspeptic symptoms,
and their exclusion criteria were similar. However, the
mean age and BMI of the HP-positive group were higher in
the Manolakis et al. study2 than in the Kebapcilar et al.
study1 (57.3¡16.1 versus 29.1¡7.5 years and 25.8¡12.7
versus 22.9¡4.5 kg/m2, respectively, after converting SEM
to SD in the first study), and these two differences could
have affected IR. There were also ethnic differences, which
might have affected IR and possibly serum fetuin-A. Finally,
in the two studies, serum fetuin-A was measured by
different commercial ELISA kits.
Fetuin-A is an acute-phase glycoprotein synthesized and
secreted almost exclusively by the liver that plays a role in
bone mineralization and insulin-signaling regulation.6
Fetuin-A binds a form of insoluble calcium phosphate,
inhibiting pathological extraosseous calcification and
thereby playing a protective role in the evolution of arterial
calcification. However, when dysregulated, fetuin-A can
lead to ectopic calcification of soft tissues in the vasculature,
thereby contributing to atherosclerosis. Likewise, by bind-
ing the extracellular portion of the b-subunit of the insulin
receptor, fetuin-A inhibits insulin-receptor tyrosine kinase,
thereby attenuating, under normal conditions, excessive
insulin signaling. However, when dysregulated, fetuin-A
results in excessive inhibition of insulin signaling in the
liver and in skeletal muscle, thereby triggering IR.
Subsequently, increased serum fetuin-A has been associated
with IR-related morbidity, including T2DM, visceral obe-
sity, NAFLD, CVD and ischemic stroke.6,7 Fetuin-A also
seems to play a role in inflammation by downregulating the
pro-inflammatory cytokines produced by macrophages.1
Fetuin-A is regarded as an anti-inflammatory mediator that
contributes to macrophage deactivation, and moreover, it
possesses anti-fibrotic activity and inhibits apoptosis in
vascular smooth muscle cells. Nonetheless, fetuin-A down-
regulates adiponectin, an anti-inflammatory and insulin-
sensitizing adipokine. Finally, although fetuin-A induces
lipid accumulation in the liver, it may attenuate hepatic
fibrosis by modifying the effects of transforming growth
factor-b signaling in hepatocytes.7 Summarizing all the
above-mentioned data, fetuin-A may possess a dual-faceted
nature in the metabolic and inflammatory milieu. It may be
protective by inhibiting extraosseous calcification or exces-
sive insulin signaling in lean, metabolically healthy indivi-
duals, but, in other situations, it may also be harmful,
especially if its action is persistently elevated and pro-
longed. This dual-faceted nature may also apply to most
cytokines and adipocytokines.8
In the Kebapcilar et al. study,1 serum fetuin-A was low in
young, HP-positive individuals with a negative history of
diabetes, obesity and known cardiovascular risk factors.
Furthermore, successful HP eradication was associated
with a fetuin-A increase and a simultaneous decrease in
both C-reactive protein and macrophage migration inhibi-
tory factor. This result seems rational for this specific
population, in whom the counteracting mechanisms,
including fetuin-A, are beneficial. In the Manolakis et al.
study,2 serum fetuin-A was increased in non-diabetic, HP-
positive individuals with established IR, who generally
were older and had a higher BMI than the HP-positive
individuals of the Kebapcilar et al. study.1 This finding also
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seems rational for this specific population, in whom the
counteracting mechanisms may no longer be beneficial,
and thus fetuin-A may contribute, at least in part, to IR. In
conclusion, serum fetuin-A may represent a promising
index for assessing the HP-related contributions to inflam-
mation, IR and IR-related conditions, including T2DM,
NAFLD and CVD; however, further clinical trials are
necessary to confirm its diagnostic efficacy.
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